rel-3-(6-(5-Chloropyridin-3-yl)-8-((1R,2R)-1-methoxy-2-methylcyclohexyl)-7-(((1S,4R)-4-methylcyclohexyl)methyl)-7H-purin-2-yl)-1,2,4-oxadiazol-5(2H)-one

Catalog No. :
ACIJWL454
CAS No. :
1621555-08-5
Molecular Formula :
C28H34ClN7O3
Molecular Weight :
552.08

IUPAC Name:3-(6-(5-chloropyridin-3-yl)-8-((1R,2R)-1-methoxy-2-methylcyclohexyl)-7-(((1r,4R)-4-methylcyclohexyl)methyl)-7H-purin-2-yl)-1,2,4-oxadiazol-5(2H)-one

rel-3-(6-(5-Chloropyridin-3-yl)-8-((1R,2R)-1-methoxy-2-methylcyclohexyl)-7-(((1S,4R)-4-methylcyclohexyl)methyl)-7H-purin-2-yl)-1,2,4-oxadiazol-5(2H)-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Namerel-3-(6-(5-Chloropyridin-3-yl)-8-((1R,2R)-1-methoxy-2-methylcyclohexyl)-7-(((1S,4R)-4-methylcyclohexyl)methyl)-7H-purin-2-yl)-1,2,4-oxadiazol-5(2H)-one
IUPAC Name3-(6-(5-chloropyridin-3-yl)-8-((1R,2R)-1-methoxy-2-methylcyclohexyl)-7-(((1r,4R)-4-methylcyclohexyl)methyl)-7H-purin-2-yl)-1,2,4-oxadiazol-5(2H)-one
Molecular FormulaC28H34ClN7O3
Molecular Weight552.08
SMILESCO[C@]1(C2=NC3=NC(C4=NC(=O)ON4)=NC(C4=CC(Cl)=CN=C4)=C3N2C[C@H]2CC[C@H](C)CC2)CCCC[C@H]1C
InChI KeyFQJJKIJLMZTVBI-PHZDQSEESA-N
CAS No.1621555-08-5

Synthetic Route by SureRoute

1. ACIJWL454 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNQSB623 route compound structure diagram
    ACNQSB623872041-85-5 In Stock
  4. Then
  5. ACIJWL454 route product structure diagram
    ACIJWL4541621555-08-5
Inquiry

2. ACIJWL454 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACIJWL454 route product structure diagram
    ACIJWL4541621555-08-5
Inquiry

Comments (0)